Chilton Investment Co Lowers stake in IDEXX Laboratories (IDXX)

IDEXX Laboratories (IDXX) : Chilton Investment Co reduced its stake in IDEXX Laboratories by 0.89% during the most recent quarter end. The investment management company now holds a total of 998,851 shares of IDEXX Laboratories which is valued at $110,652,714 after selling 8,939 shares in IDEXX Laboratories , the firm said in a disclosure report filed with the SEC on Aug 11, 2016.IDEXX Laboratories makes up approximately 3.76% of Chilton Investment Co’s portfolio.

Other Hedge Funds, Including , Engineers Gate Manager Lp reduced its stake in IDXX by selling 6,943 shares or 10.75% in the most recent quarter. The Hedge Fund company now holds 57,624 shares of IDXX which is valued at $6,383,587. IDEXX Laboratories makes up approx 0.43% of Engineers Gate Manager Lp’s portfolio.Tocqueville Asset Management boosted its stake in IDXX in the latest quarter, The investment management firm added 1,525 additional shares and now holds a total of 6,025 shares of IDEXX Laboratories which is valued at $565,085. IDEXX Laboratories makes up approx 0.01% of Tocqueville Asset Management’s portfolio. Advisory Services Network added IDXX to its portfolio by purchasing 29 company shares during the most recent quarter which is valued at $2,690.Parkwood reduced its stake in IDXX by selling 2,435 shares or 4.65% in the most recent quarter. The Hedge Fund company now holds 49,887 shares of IDXX which is valued at $4,711,328. IDEXX Laboratories makes up approx 0.77% of Parkwood’s portfolio.

IDEXX Laboratories opened for trading at $110.36 and hit $111.38 on the upside on Tuesday, eventually ending the session at $110.68, with a gain of 0.20% or 0.22 points. The heightened volatility saw the trading volume jump to 3,79,547 shares. Company has a market cap of $9,910 M.

On the company’s financial health, IDEXX Laboratories reported $0.74 EPS for the quarter, beating the analyst consensus estimate by $ 0.12 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.62. The company had revenue of $466.56 million for the quarter, compared to analysts expectations of $445.57 million. The company’s revenue was up 12.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.60 EPS.

Many Wall Street Analysts have commented on IDEXX Laboratories. Company shares were Reiterated by Stifel on Aug 16, 2016 to “Buy”, Firm has raised the Price Target to $ 125 from a previous price target of $120 .IDEXX Laboratories was Upgraded by Northcoast to ” Neutral” on Aug 3, 2016. Company shares were Reiterated by Canaccord Genuity on Jul 20, 2016 to “Buy”, Firm has raised the Price Target to $ 98 from a previous price target of $90 .

IDEXX Laboratories Inc. develops manufactures and distributes products and provides services primarily for the companion animal veterinary livestock and poultry water testing and dairy markets. The Company sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its segments include Companion Animal Group (CAG) Water Livestock Poultry and Dairy and Other. Its Products and services include point-of-care veterinary diagnostic products; veterinary reference laboratory diagnostic and consulting services; practice management systems and services and digital imaging systems; biological materials testing laboratory animal diagnostic instruments and services; diagnostic health-monitoring and food safety testing products for livestock poultry and dairy; products that test water for microbiological contaminants and point-of-care electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Leave a Reply

IDEXX Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on IDEXX Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.